Candel's Aglatimagene Shows 24.5-Month Survival in NSCLC Patients Failing Immunotherapy
CADL has more than doubled off its 52-week low of $4.35.
Summary
Candel published final Phase 2a data in the Journal for ImmunoTherapy of Cancer showing aglatimagene plus valacyclovir achieved a median overall survival of 24.5 months in evaluable patients with unresectable stage III/IV NSCLC who had inadequate response to immune checkpoint inhibitors. That compares to 9.8-11.8 months for standard-of-care docetaxel. In the subgroup with progressive disease on ICI (n=41), mOS was 21.5 months, and 37% remained alive beyond 24 months. Non-squamous patients did even better: mOS of 25.4 months, with 14 of 15 surviving beyond 24 months. Mechanistic data showed 69% of patients with multiple lesions had systemic clinical response, indicating an abscopal effect. Safety was manageable with mostly grade 1-2 flu-like symptoms and 13.7% grade 3 treatment-related adverse events. This follows the ASTRO 2026 biomarker presentation on September 30 and supports the ongoing pivotal Phase 3 AURORA trial in metastatic non-squamous NSCLC. The peer-reviewed publication provides independent validation and could strengthen the case for regulatory discussions. Watch for AURORA trial enrollment updates and any FDA interactions.
At the time of this announcement, CADL was trading at $10.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $798.9M. The 52-week trading range was $4.35 to $14.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.